Senti Biosciences Inc SNTI.OQ SNTI.O is expected to show a rise in quarterly revenue when it reports results on March 18 (estimated) for the period ending December 31 2025
The South San Francisco California-based company is expected to report revenue of $666.67 thousand, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Senti Biosciences Inc is for a loss of 41 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Senti Biosciences Inc is $12.50, about 1,241.9% above its last closing price of $0.93
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.58 | -0.57 | -0.69 | Missed | -21.8 |
Jun. 30 2025 | -0.90 | -0.90 | -0.56 | Beat | 37.8 |
| |||||
Dec. 31 2024 | -3.13 | -3.13 | -0.67 | Beat | 78.6 |
| |||||
|
This summary was machine generated March 16 at 20:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments